InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,617.20
(
0.04%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.87
(
-0.73%
)
Bitcoin
62,447.92
(
-1.14%
)
Post# of 216
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

TREND1

Send PM Follow Ignore
Followers 417
Posts 52354
Boards Moderated 13
Alias Born 12/16/2001

TREND1

Member Level

Re: None

Thursday, 11/30/2017 12:07:01 PM

Thursday, November 30, 2017 12:07:01 PM

Post# of 216
11/30 Could The FDA's Less Stringent Regulations Help MannKind?


•FDA Commissioner recently issued new guidance, making it easier for generics competing against EpiPen to gain approval.

•Technosphere epinephrine, if properly developed and promoted, can enjoy prompt approval (as well as substantial sales).

•The anaphylaxis market is currently dominated by Mylan’s EpiPen, but Technosphere epinephrine can change that.



https://seekingalpha.com/article/4128641-fdas-less-stringent-regulations-help-mannkind?auth_param=1vat:1d1v583:2e8d1ee07ef022e938d783acf01d8127&uprof=51

TRADING 01 LIST https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133836402

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up